T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer


Study Number
68018
Phase
2
Purpose

This is a randomized phase II study to evaluate if the combination of T-DM1 with palbociclib improves progression-free survival compared to single agent T-DM1in patients with metastatic HER2 positive breast cancer

Full Title

A randomized phase II study to evaluate efficacy of TDM1with or without Palbociclib in the treatment of patients with metastatic HER2 positive breast cancer

ClinicalTrials.Gov ID
NCT03530696

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.